Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH)

Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation

(2021) Hong-Yue Lai et al.   Frontiers in Cell and Developmental Biology

Factors influencing the short-term and long-term survival of hepatocellular carcinoma patients with portal vein tumor thrombosis who underwent chemoembolization

(2021) Ke-Li Chen et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis

(2020) Jiao Feng et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study

(2020) Satoshi Noda et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial)

(2020) Ioana Riaño et al.   Cancers

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats

(2020) Agnieszka Karbownik et al.   Pharmaceutics

Pravastatin combination with Sorafenib does not improve survival in advanced Hepatocellular Carcinoma

(2019) Jean-Louis Jouve et al.   JOURNAL OF HEPATOLOGY

Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials

(2017) Richard Jackson et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies

(2017) Jordi Bruix et al.   JOURNAL OF HEPATOLOGY

Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection

(2015) Yao-Hsu Yang et al.   JOURNAL OF HEPATOLOGY

Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma

(2015) Miki Shimada et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Fas/Fas Ligand Mediates Keratinocyte Death in Sunitinib-Induced Hand-Foot Skin Reaction

(2014) Chun-Nan Yeh et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

(2013) R. Lencioni et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Has the time come for metronomics in low-income and middle-income countries?

(2013) Nicolas André et al.   LANCET ONCOLOGY

Metformin pathways

(2012) Li Gong et al.   Pharmacogenetics and Genomics

Population pharmacokinetic analysis of sorafenib in patients with solid tumours

(2011) Lokesh Jain et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy

(2011) Massimo Iavarone et al.   HEPATOLOGY

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin

(2010) U. N. Vaishampayan et al.   CLINICAL CANCER RESEARCH

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

(2008) Hironobu Minami et al.   CANCER SCIENCE

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE